|
| Wednesday, December 20, 2017 |
|
|
Jacobson Pharma Enters Agreements with Shanghai Henlius Biotech Inc. To Tap Biologics Market |
| Jacobson Pharma Corporation Limited today announced that through its wholly-owned subsidiaries, Jacobson Medical (Hong Kong) Limited and Joyful Ascent Limited, it has entered into a Licensing Framework Agreement and a Capital Increase Agreement with a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. namely, Shanghai Henlius Biotech Inc., a technological leader in research and development of biosimilar antibody drugs in China. more info >> |
|
|
Jacobson Pharma Enters Agreements with Shanghai Henlius Biotech Inc. To Tap Biologics Market |
| Jacobson Pharma Corporation Limited ("Jacobson Group" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines more info >> |
|
| Wednesday, November 22, 2017 |
|
|
Jacobson Pharma Announces FY2018 Interim Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its unaudited interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2017 (the "Reporting Period"). more info >> |
|
| Tuesday, October 3, 2017 |
|
|
Jacobson Pharma Issues HK$500M Convertible Notes to Dragons 615 Ltd and HH InRe JP, Ltd. |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines more info >> |
|
| Wednesday, September 6, 2017 |
|
|
Jacobson Pharma Issues HK$500M of Convertible Notes to Dragons 615 and HH InRe JP, Ltd. |
| Jacobson Pharma Corporation Limited , a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has proposed to issue Convertible Notes under general mandate, in an aggregate principal amount of HK$500 million due in 2020, to two subscribers namely Dragons 615 Limited and HH InRe JP, Ltd. more info >> |
|
| Sunday, June 25, 2017 |
|
|
Jacobson Pharma Announces 2017 Annual Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has today announced its annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2017 ( "FY 2017" ). more info >> |
|
| Monday, March 13, 2017 |
|
|
Jacobson Pharma Announces Acquisition of 70% Interest in Hong Ning Hong |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production more info >> |
|
| Wednesday, January 18, 2017 |
|
|
Jacobson Pharma to Acquire Saplingtan, Shiling Oil & Col-gan Tablet; Creating an Expandable Proprietary Medicine Platform |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its acquisition of a family of popular household brands, namely, Saplingtan, Shiling Oil and Col-gan Tablet.
more info >> |
|
| Tuesday, December 13, 2016 |
|
|
Jacobson Pharma Announces Acquisition of 100% Interest in Ho Chai Kung Brand |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary Chinese medicines, today announces the acquisition of 100% interest in a Target Group (comprising "Karen Pharmaceutical Company Limited" more info >> |
|
| Wednesday, November 23, 2016 |
|
|
Jacobson Pharma Announces 2016 Interim Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development more info >> |
|
|
|
